Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

MLM Medical Labs GmbH. (8/19/20). "Press Release: MLM Medical Labs Appoints Isabel Struik as VP Sales & Marketing". Düsseldorf.

Organisations Organisation MLM Medical Labs GmbH
  Group MLM Medical Labs (Group)
  Organisation 2 Great Point Partners LLC
Products Product laboratory services
  Product 2 contract research (drugs)
  Index term 2 CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs
Persons Person Struik, Isabel (MLM Medical Labs 202008– VP Sales + Marketing)
  Person 2 Wnendt, Stephan (MLM Medical Labs 200801– CEO before Paion Deutschland + ViaCell + Kourion Therapeutics)
     


MLM Medical Labs GmbH (“MLM”), a Great Point Partners (“GPP”) portfolio company, today announced that Isabel Struik has joined the team as VP Sales & Marketing. Isabel holds a degree in toxicological sciences of the University of Wageningen, The Netherlands. She has been working in contract research for over 23 years, mostly in the field of clinical trials and central laboratory services for European and US-based companies.

“We are very happy to welcome Isabel to our team and are convinced that Isabel will leverage her experience in clinical trials to the benefit of our customers and our company. Especially after the recent acquisition of our US based laboratory in Memphis, we are eager to further expand our sales and marketing activities. We want to keep the momentum with globally active biotech and pharma customers that need central lab services for their clinical development programmes, to develop medicines to save and improve lives across the globe.” said Stephan Wnendt, CEO of MLM.

“I am delighted to join MLM at these exciting times for the company, I see a vast potential for future growth based due to the high flexibility of MLM, its quality standards that exceeds customer expectation, its broad analytical capabilities and innovative solutions in kit building and customer friendly digitalsolutions” added Isabel Struik. “Therefore, I am thrilled to be a part of MLM’s success story going forward. The current pandemic has clearly shown the importance of clinical trials for medical innovation. MLM has been on the forefront of clinical research as being involved as central lab for COVID-19 vaccination trials.”

Isabel will be located in MLM’s German 38,000 sq ft facility in Moenchengladbach, close to Duesseldorf, Germany. Isabel Struik can be reached under istruik@mlm-labs.com or +49 2161 46 42 108.


About MLM Medical Labs

MLM Medical Labs founded 1993 is a Central Laboratory dedicated exclusively to clinical trials. MLM offers a full range of laboratory services, including specialized biomarker testing, clinical chemistry, standard safety profiles, clinical chemistry, and analyses of drug compounds, metabolites and molecular diagnostic parameters. Internationally active in over 40 countries, including the U.S. and Eastern Europe, MLM is headquartered in Moenchengladbach, Germany (near Duesseldorf International Airport). In July 2020 MLM expanded its laboratory operations to the US by acquiring CirQuest Labs of Memphis, TN. MLM works 365 days a year in order to ensure valid, high-quality, results with a quick turnaround time. In December 2019 MLM became a Great Point Partner portfolio company.

For more information, please visit
https://www.mlm-labs.com/


About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $2.2 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $306 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.6 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at +1203-971-3300 or www.gppfunds.com.

   
Record changed: 2020-09-04

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for MLM Medical Labs (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] No Content Marketing 650x80px




» top